Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation plc (NASDAQ: AMRN) announced a live webcast on February 14, 2023, from 8:00 a.m. to 9:00 a.m. ET. Members of the Board and management team will address shareholder questions regarding the company’s strategy and operational improvements. Shareholders can submit questions in advance. The upcoming General Meeting of Shareholders is set for February 28, 2023, with record shareholders entitled to vote. Amarin urges shareholders to vote 'AGAINST' all proposals on the WHITE proxy card. Voting deadlines vary for ADS and ordinary shares. For investor assistance, proxy solicitors are available. More information can be found at www.voteamarin.com.
Sarissa Capital Management LP has issued a statement regarding Amarin Corporation (NASDAQ: AMRN), accusing the company of wasting shareholder capital. Amarin plans to spend over $7 million to block Sarissa from board representation, which is significantly more than Sarissa's planned expenditure. The statement highlights past financial mismanagement, including substantial compensation granted to executives despite significant stock declines, totaling over $1.4 billion in shareholder losses in 2021 and 2022. Sarissa advocates for shareholder action to remove Chairman Per Wold-Olsen and supports change in leadership.
Sarissa Capital Management has issued a letter urging Amarin shareholders to vote for significant changes at the company, including the appointment of new board members and the removal of Chairman Per Wold-Olsen.
They criticize Amarin’s leadership for poor performance, highlighted by a 64% decline in stock price in 2022, equating to a loss of over $840 million in shareholder value. Furthermore, Sarissa points to management’s ineffective market strategies and lack of shareholder engagement as contributing factors to Amarin's failure to capitalize on its valuable asset, Vascepa/Vazkepa.
Sarissa urges action before the February 21, 2023 voting deadline to prevent further value destruction.
Amarin Corporation (NASDAQ: AMRN) has mailed a letter urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card at the scheduled General Meeting on February 28, 2023. The letter highlights a significant shift in the company's management and strategy, emphasizing that Amarin is undergoing a transformation and has the right team to drive shareholder value. The letter accuses Sarissa of misleading shareholders with a track record of value destruction, citing that companies with Sarissa-affiliated directors have seen a NEGATIVE 24% total shareholder return. Amarin's management is committed to maximizing value, including potential M&A opportunities.
Sarissa Capital Management urges Amarin shareholders to vote the BLUE proxy card ahead of the general meeting on February 28, 2023. Shareholders should ensure their votes are submitted by February 21, 2023. Sarissa's presentation highlights inaccuracies in Amarin's statements aimed at protecting its board, advocating for the election of Sarissa’s nominees and the removal of Chairman Per Wold-Olsen. Shareholders are encouraged to refrain from using Amarin’s WHITE proxy card, with additional details available on Sarissa's website and through its proxy solicitor, D.F. King & Co., Inc.
Amarin Corporation (NASDAQ: AMRN) sent a letter to shareholders urging them to vote "AGAINST" Sarissa Capital's proposals during the upcoming General Meeting set for February 28, 2023. The company criticized Sarissa for spreading misleading information and attempting to take control of the board with underqualified nominees. Key points include Sarissa's historical negative impact on shareholder value, with a median total shareholder return of -24% at companies with Sarissa-nominated directors. Amarin emphasizes its commitment to maximizing shareholder value and has initiated cost-saving measures, achieving $50 million in reductions in 2022.
Sarissa Capital Management has launched a dedicated website for Amarin Corporation shareholders, emphasizing the importance of voting with the BLUE proxy card by February 21, 2023, at 11:59 PM EST. The proxy card will allow shareholders to support Sarissa's slate of nominees at Amarin's upcoming general meeting on February 28, 2023. Sarissa advises against using Amarin’s WHITE proxy card. Shareholders can access important documents via the SEC website or Sarissa's site for further instructions on voting and to view their presentation.
Amarin Corporation plc (NASDAQ: AMRN) urges shareholders to vote against all proposals by Sarissa Capital Management at the upcoming General Meeting on February 28, 2023. The company emphasizes its newly appointed Board, led by Chairman Per Wold-Olsen, is executing a transformative strategy to enhance shareholder value. Key achievements include securing six international regulatory approvals in 2022, stabilizing U.S. revenue for four consecutive quarters, and implementing a $100 million annual cost savings plan. Amarin's leadership asserts that Sarissa’s proposed changes could jeopardize the company's progress.
Sarissa Capital Management is urging Amarin Corporation (NASDAQ: AMRN) shareholders to support their nominees for the board and remove Chairman Per Wold-Olsen at the upcoming general meeting on February 22, 2023. They emphasize the 64% stock decline in 2022, which resulted in over $840 million lost in shareholder value due to alleged mismanagement. Sarissa argues that adding their nominees will help maximize shareholder value based on their successful track record in the healthcare sector. They contend that the current leadership is obstructing accountability and shareholder representation, further advocating for the vote before key deadlines.
Amarin Corporation plc (NASDAQ: AMRN) has filed definitive proxy materials with the SEC for its upcoming General Meeting on February 28, 2023. Shareholders are urged to vote "AGAINST" Sarissa Capital Management's proxy proposals, arguing that Sarissa lacks a constructive plan and has presented an underqualified slate of nominees. Over the past 18 months, Amarin has revamped its leadership and board, focusing on geographic expansion and enhancing operational efficiency. The company is confident in achieving up to $1 billion in revenue opportunities through its strategies, despite facing generic competition in the U.S.